The PDUFA action date for an FDA decision for linvoseltamab to treat adult patients with relapsed/refractory multiple myeloma ...

Columbus’ John B Amos Cancer Center is now leading the way to administer a new cancer treatment in the Peach State.The ...

Throughout my experience with multiple myeloma, I was humbled by the unexpected support and kindness shown to me.

Linvoseltamab is an investigational BCMAxCD3 bispecific antibody designed to bridge B-cell maturation antigen (BCMA) on MM cells with CD3-expressing T cells to facilitate T-cell activation and ...

So, we now have multiple new classes of drugs, multiple agents that are FDA-approved for the treatment of multiple myeloma, more than 15, 16 different drugs that have become available in that period.

The following is a summary of “Time-dependent recovery of renal impairment in patients with newly diagnosed multiple myeloma, ...

People are living longer, living better with multiple myeloma. But I think for the vast majority of people who are diagnosed, we still don't have a curative treatment for multiple myeloma, so that, to ...

When blood cancer cells break through the bone and multiply, tumor cells become dangerously diverse and the immune response ...

The panelist discusses how for managing patients with R/R multiple myeloma, community clinicians should focus on personalized ...

Regeneron (REGN) announced that the U.S. Food and Drug Administration has accepted for review the resubmission of the Biologics License ...

Panelists discuss how to navigate and choose among multiple guideline-recommended induction regimens for patients with ...